LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

30.38 -0.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.38

Massimo

30.79

Metriche Chiave

By Trading Economics

Entrata

-16M

-97M

Vendite

361K

361K

EPS

-1.04

Margine di Profitto

-26,807.202

Dipendenti

437

EBITDA

-17M

-110M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+142.54% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-373M

2.8B

Apertura precedente

30.41

Chiusura precedente

30.38

Notizie sul Sentiment di mercato

By Acuity

50%

50%

134 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2025, 23:56 UTC

Discorsi di Mercato

Oil Rises Amid Geopolitical Tensions -- Market Talk

1 giu 2025, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

1 giu 2025, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline as Tariff Uncertainty Continues -- Market Talk

1 giu 2025, 23:45 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

1 giu 2025, 23:44 UTC

Discorsi di Mercato

Gold Rises After Trump Threatens to Double Steel, Aluminum Tariffs -- Market Talk

1 giu 2025, 23:39 UTC

Discorsi di Mercato

Coles Bull Stands Firm Despite Temptation to Favor Woolworths -- Market Talk

31 mag 2025, 10:30 UTC

Notizie principali

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mag 2025, 06:30 UTC

Utili

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mag 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 23:51 UTC

Acquisizioni, Fusioni, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mag 2025, 21:30 UTC

Notizie principali

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mag 2025, 21:15 UTC

Notizie principali

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mag 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

30 mag 2025, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mag 2025, 20:24 UTC

Notizie principali

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mag 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 19:44 UTC

Discorsi di Mercato

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mag 2025, 19:38 UTC

Discorsi di Mercato

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mag 2025, 19:29 UTC

Utili
Acquisizioni, Fusioni, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mag 2025, 19:14 UTC

Discorsi di Mercato

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mag 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mag 2025, 18:51 UTC

Discorsi di Mercato

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mag 2025, 18:37 UTC

Discorsi di Mercato
Utili

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mag 2025, 18:04 UTC

Notizie principali

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mag 2025, 17:40 UTC

Acquisizioni, Fusioni, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mag 2025, 17:38 UTC

Discorsi di Mercato

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mag 2025, 17:31 UTC

Discorsi di Mercato

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mag 2025, 17:14 UTC

Notizie principali

American Consumers Are Still Gloomy on the Economy -- 3rd Update

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

142.54% in crescita

Previsioni per 12 mesi

Media 74 USD  142.54%

Alto 97 USD

Basso 53 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

134 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.